OMOlivia L. McGovern

Olivia L. McGovern

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olivia L. McGovern has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Maureen H. Diaz

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    2 shared publications
  • Aaron T. Curns

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication
  • Alessandra P A Gurgel

    Hospital Alemao Oswaldo Cruz , Sao Paulo , Brazil

    1 shared publication
  • Alexandra M. Oster

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication
  • Alicia M. Fry

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication
  • Allan W. Taylor

    Affiliation CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Trends in Inpatient Antibiotic Use Among Adults Hospitalized During the Coronavirus Disease 2019 Pandemic in Argentina, Brazil, and Chile, 2018–2021

    by Twisha S Patel, Olivia L McGovern, Garrett Mahon, Hanako Osuka, Icaro Boszczowski, Jose M Munita, Maria Isabel Garzon, Matias C Salomao, Giovanna Marssola, Bruno M Tavares, et al.

    High rates of antibiotic use (AU) among inpatients with coronavirus disease 2019 (COVID-19) despite low rates of bacterial coinfection and secondary infection have been reported. We evaluated the impact of the COVID-19 pandemic on AU in healthcare facilities (HCFs) in South America. We conducted an ecologic evaluation of AU in inpatient adult acute care wards in 2 HCFs each in Argentina, Brazil, and Chile. The AU rates for intravenous antibiotics were calculated as the defined daily dose per 1000 patient-days, using pharmacy dispensing records and hospitalization data from March 2018–February 2020 (prepandemic) and March 2020–February 2021 (pandemic). Differences in median AU were compared between the prepandemic and pandemic periods, using the Wilcoxon rank sum test to determine significance. Interrupted time series analysis was used to analyze changes in AU during the COVID-19 pandemic. Compared with the prepandemic period, the median difference in AU rates for all antibiotics combined increased in 4 of 6 HCFs (percentage change, 6.7%–35.1%; P < .05). In the interrupted time series models, 5 of 6 HCFs had significant increases in use of all antibiotics combined immediately at the onset of the pandemic (immediate effect estimate range, 15.4–268), but only 1 of these 5 HCFs experienced a sustained increase over time (change in slope, +8.13; P < .01). The effect of the pandemic onset varied by antibiotic group and HCF. Substantial increases in AU were observed at the beginning of the COVID-19 pandemic, suggesting the need to maintain or strengthen antibiotic stewardship activities as part of pandemic or emergency HCF responses.


  • Open Access

    Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019—United States, January 17–February 29, 2020

    by Olivia L. McGovern, Mark Stenger, Sara E. Oliver, Tara C. Anderson, Cheryl Isenhour, Matthew R. Mauldin, Nia Williams, Eric Griggs, Tonny Bogere, Chris Edens, et al.

    The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020. In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17−February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios. A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures. These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.


  • Open Access

    Use of Real-Time PCR for Chlamydia psittaci Detection in Human Specimens During an Outbreak of Psittacosis — Georgia and Virginia, 2018

    by Olivia L. McGovern, Miwako Kobayashi, Kelly A. Shaw, Christine Szablewski, Julie Gabel, Caroline Holsinger, Cherie Drenzek, Skyler Brennan, Jennifer Milucky, Jennifer L. Farrar, et al.

    This report describes testing used during a psittacosis outbreak in 2018.


  • Open Access

    Differential protein phosphorylation affects the localisation of two secreted Toxoplasma proteins and is widespread during stage conversion

    by Joanna Young, Malgorzata Broncel, Helena Teague, Matthew R Russell, Olivia McGovern, Matt Renshaw, David Frith, Bram Snijders, Lucy M Collinson, Vern B. Carruthers, et al.

    The intracellular parasite Toxoplasma gondii resides within a membrane bound parasitophorous vacuole (PV) and secretes an array of proteins to establish this replicative niche. It has been shown previously that Toxoplasma both secretes kinases and that numerous proteins are phosphorylated after secretion. Here we assess the role of phosphorylation of SFP1 and the related GRA29, two secreted proteins with unknown function. We show that both proteins form stranded structures in the PV that are independent of the previously described intravacuolar network or actin. GRA29 likely acts as a seed for SFP1 strand formation, and these structures can form independently of other Toxoplasma secreted proteins. We show that an unstructured region at the C-terminus of SFP1 and GRA29 is required for the formation of strands and that mimicking phosphorylation of this domain negatively regulates strand development. When tachyzoites convert to chronic stage bradyzoites, both proteins show a dispersed localisation throughout the cyst matrix. Many secreted proteins are reported to dynamically redistribute as the cyst forms and secreted kinases are known to play a role in cyst formation. Using quantitative phosphoproteome and proteome analysis comparing tachyzoite and early bradyzoite stages, we reveal widespread differential phosphorylation of secreted proteins. These data support a model in which secreted kinases and phosphatases are important to dynamically regulate parasite secreted proteins during stage conversion. IMPORTANCE: Toxoplasma gondii is a common parasite that infects up to one third of the human population. Initially the parasite grows rapidly, infecting and destroying cells of the host, but subsequently switches to a slow-growing form and establishes chronic infection. In both stages the parasite lives within a membrane bound vacuole within the host cell, but in the chronic stage a durable cyst wall is synthesized that provides protection to the parasite during transmission to a new host. Toxoplasma secretes proteins into the vacuole to build its replicative niche and previous studies identified many of these proteins as phosphorylated. We investigate two secreted proteins and show that phosphorylation plays an important role in their regulation. We also observed widespread phosphorylation of secreted proteins when parasites convert from acute to chronic stages, providing new insight into how the cyst wall may be dynamically regulated.